What is Biomea Fusion, Inc.'s (BMEA) StockRank?

MoatMap's StockRank for Biomea Fusion, Inc. (BMEA) is 10/100, with a Strong Sell signal. This is a composite score combining Quality (27), Value (33), and Momentum (34) factor ranks across MoatMap's 20,000+ stock universe.

Does Biomea Fusion, Inc. have an economic moat?

Biomea Fusion, Inc. (BMEA) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Biomea Fusion, Inc. a buy, hold, or sell?

MoatMap's current signal for Biomea Fusion, Inc. (BMEA) is Strong Sell, based on a StockRank of 10/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Biomea Fusion, Inc. in?

Biomea Fusion, Inc. (BMEA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

BMEA

STRONG SELLREMOVE

Biomea Fusion, Inc. · Healthcare · United States · $100M · Avg Vol: $1M/d

StockRank

P/E (TTM)

—

ROE

-189.4%

D/E

0.1x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Biomea Fusion is a clinical-stage biotech focused on covalent therapies. High cash burn and binary clinical outcomes make it unsuitable for a concentrated quality book.

COMPANY DESCRIPTION

Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company focused on developing novel covalent small molecule drugs to treat cancer and other serious diseases. The company's lead product candidates are designed to specifically target and permanently bind to disease-driving proteins, offering potentially more durable and efficacious therapeutic options. Its proprietary FUSION System platform underpins its competitive strategy, aiming to create best-in-class covalent medicines.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0	0	0	0	—
EPS	-2.80	-3.44	-3.83	-1.18	—
Shares	30M	36M	36M	72M	+144.6%
Debt	2M	10M	9M	2M	-11.4%
Equity	109M	169M	52M	30M	-35.2%
Op CF	-62M	-97M	-120M	-70M	—
Inv CF	27M	-2M	-362,000	0	—
Fin CF	1M	164M	2M	68M	—

PRICE (1M)-25.0%

SMA 50SMA 200

$1.20

RSI (14)

34.7

52W High

$3.08

From 52W High

0.4%

SCORE BREAKDOWN

Quality

ROIC

-171.3%2.6

ROE

-189.4%3.8

GP/Assets

—N/A

Op. Margin

0.0%40.4

FCF/Assets

-56.1%3.8

Piotroski

—7.2

Int. Cover

—N/A

D/E Ratio

0.07x71.7

Current Ratio

4.98x70.8

Value

P/E (TTM)

—N/A

EV/EBITDA

-0.6x63.7

P/FCF

—N/A

P/B

4.5x27.0

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

39%11.4

RS 6M

-20%56.5

SMA 50/200

1.03x69.1

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-101%4.4

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$100M

P/E (Forward)

-1.1x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BMEA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
BMEA	Biomea Fusion, Inc.(you)	$100M	10	STRONG SELL
CGTX	Cognition Therapeutics, Inc.	$107M	9	STRONG SELL
COYA	Coya Therapeutics, Inc.	$113M	11	STRONG SELL
PEPG	PepGen Inc.	$104M	7	STRONG SELL
AARD	Aardvark Therapeutics, Inc.	$92M	7	STRONG SELL
ANIX	Anixa Biosciences, Inc.	$91M	7	STRONG SELL
GOSS	Gossamer Bio, Inc.	$79M	9	STRONG SELL
FLNA	Filana Therapeutics, Inc.	$75M	11	STRONG SELL
2257.HK	Sirnaomics Ltd.	$82M	7	STRONG SELL
ALDX	Aldeyra Therapeutics, Inc.	$106M	5	STRONG SELL

Peer medians: ROE -22.4% · P/E 25.3x · Gross margin 44.3%

Biomea Fusion, Inc. (BMEA) — Stock Score Summary

Biomea Fusion, Inc. (BMEA) has a MoatMap StockRank of 10/100 based on Quality (27/100), Value (33/100), and Momentum (34/100) factor scores. The current signal is STRONG SELL. Biomea Fusion is a clinical-stage biotech focused on covalent therapies. High cash burn and binary clinical outcomes make it unsuitable for a concentrated quality book.

Key Financial Metrics

Price	$1.20
Market Cap	$100M
P/E (Forward)	-1.06
Price/Book	4.52
Return on Equity	-189.4%
Return on Invested Capital	-171.3%
Debt/Equity	6.62
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-33M

Biomea Fusion, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Biomea Fusion, Inc.’s (BMEA) StockRank?: MoatMap’s StockRank for Biomea Fusion, Inc. (BMEA) is 10/100, with a Strong Sell signal. It is a composite of Quality (27), Value (33), and Momentum (34) factor ranks across MoatMap’s 20,000+ stock universe.
Does Biomea Fusion, Inc. have an economic moat?: Biomea Fusion, Inc. (BMEA) has a Quality factor score of 27/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Biomea Fusion, Inc. a buy, hold, or sell?: MoatMap’s current signal for Biomea Fusion, Inc. (BMEA) is Strong Sell, based on a StockRank of 10/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Biomea Fusion, Inc. in?: Biomea Fusion, Inc. (BMEA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).